Home » Stocks » GOVX

GeoVax Labs, Inc. (GOVX)

Stock Price: $2.90 USD 0.22 (8.21%)
Updated November 30, 4:00 PM EST - Market closed
After-hours: $2.88 -0.02 (-0.69%) Nov 30, 7:51 PM

Stock Price Chart

Key Info

Market Cap 11.05M
Revenue (ttm) 1.84M
Net Income (ttm) -2.21M
Shares Out 3.81M
EPS (ttm) -1.84
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 30
Last Price $2.90
Previous Close $2.68
Change ($) 0.22
Change (%) 8.21%
Day's Open 2.81
Day's Range 2.70 - 2.95
Day's Volume 840,982
52-Week Range 2.63 - 3.65

More Stats

Market Cap 11.05M
Enterprise Value n/a
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 3.81M
Float n/a
EPS (basic) 14,011.64
EPS (diluted) -1.84
FCF / Share -1.91
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 29,075
Short Ratio 0.00
Short % of Float n/a
Beta 1.35
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 6.00
PB Ratio 1.02
Revenue 1.84M
Operating Income -2.07M
Net Income -2.21M
Free Cash Flow -1.50M
Net Cash 11.39M
Net Cash / Share 2.99
Gross Margin -48.10%
Operating Margin -112.51%
Profit Margin -120.20%
FCF Margin -81.24%
ROA -217.33%
ROE n/a
ROIC 131.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (1)

Buy 1
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

Current: $2.90
Target: 8.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth22.08%-10.42%29.72%93.64%-51.52%-63.48%-9.02%-45.77%-5.5%-
Gross Profit1.180.961.080.830.430.882.422.664.905.19
Operating Income-2.37-2.56-2.17-3.27-2.69-2.74-2.29-2.14-2.35-2.77
Net Income-2.37-2.56-2.17-3.27-2.69-2.73-2.28-2.14-2.35-2.75
Shares Outstanding3.020.01--------
Earnings Per Share-785.00-312,206.60-600,000.00-1,600,000.00-1,600,000.00-2,000,000.00-2,200,000.00-2,400,000.00-3,000,000.00-3,600,000.00
Operating Cash Flow-1.40-1.54-1.69-1.95-2.71-2.25-1.69-2.44-0.30-2.44
Capital Expenditures-0.01----0.02-0.04-0.09--0.01-
Free Cash Flow-1.41-1.54-1.69-1.95-2.72-2.29-1.78-2.44-0.32-2.44
Cash & Equivalents0.290.270.320.471.061.102.511.041.171.08
Total Debt0.040.30--------
Net Cash / Debt0.25-0.030.320.471.061.102.511.041.171.08
Book Value-1.57-1.02-0.320.
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name GeoVax Labs, Inc.
Country United States
Employees 6
CEO David A. Dodd

Stock Information

Ticker Symbol GOVX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: GOVX


GeoVax Labs, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform in the United States and internationally. It is developing various preventive vaccines against coronavirus (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for chronic Hepatitis B infections and cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; the HIV Vaccines Trial Network; Centers for Disease Control and Prevention; U.S. Department of Defense; U.S. Army Research Institute of Infectious Disease; U.S. Naval Research Laboratory; Emory University; University of Pittsburgh; Georgia State University Research Foundation; University of Texas Medical Branch; the Institute of Human Virology at the University of Maryland; the Scripps Research Institute; the Burnet Institute; American Gene Technologies International, Inc.; Viamune, Inc.; Vaxeal Holding SA; Virometix AG; Geneva Foundation; Enesi Pharma; UCSF; BravoVax; and Leidos, Inc. GeoVax Labs, Inc. was founded in 2001 and is based in Smyrna, Georgia.